A recent comprehensive study has shed light on the controversial topic of prostate cancer screening, revealing that while blood tests can save lives, the overall benefit remains modest. This research raises crucial questions about the balance between the potential life-saving advantages and the risks of unnecessary treatments.
Screening Efficacy and Limitations
The analysis, which reviewed six trials involving nearly 800,000 men, found that screening with the prostate-specific antigen (PSA) test reduces prostate cancer mortality by two deaths for every 1,000 men screened. This translates to the necessity of screening approximately 500 men to prevent a single death from the disease. The benefits of screening became more evident during long-term follow-ups, particularly highlighted by the European Randomized Study of Screening for Prostate Cancer (ERSPC), which tracked participants for up to 23 years.
Professor Philipp Dahm, a urologist at the University of Minnesota and the senior author of the Cochrane review, stated, “Prostate cancer screening does reduce prostate cancer mortality, although the caveat is that it takes a very extended period of time to realise that benefit.” This insight could prove pivotal for policymakers as they navigate the complexities of screening programmes.
The Challenge of Overdiagnosis
Despite the findings, the UK and many other nations lack formal prostate cancer screening programmes, largely due to the PSA test’s unreliability. While the test identifies life-threatening tumours, it also detects many benign cancers that pose no threat, leading to a range of unnecessary treatments such as radiotherapy or surgery. Such interventions can leave men vulnerable to complications, including incontinence and erectile dysfunction.
The review did not thoroughly investigate how screening affects men’s quality of life, although the ProtecT trial indicated that between 8% and 47% of men experienced issues with urinary or sexual function post-treatment. Dr Juan Franco from Heinrich Heine University in Düsseldorf, the lead author of the review, emphasised that these results do not advocate for universal screening. He warned of the “very real risks” associated with overdiagnosis and unnecessary treatment, advocating for shared decision-making between doctors and patients.
Current Recommendations and Future Directions
Prostate cancer is a significant health concern, with over 64,000 new cases diagnosed annually in the UK alone, affecting one in eight men in their lifetime—this risk increases to one in four for Black men. Last year, the UK National Screening Committee advised against general prostate cancer screening, instead suggesting a targeted approach for individuals with BRCA1 and BRCA2 mutations linked to more aggressive forms of cancer. This guidance is currently under review by government officials.
Professor Dahm noted that screening is more beneficial for men who are likely to live for another 10 to 15 years. “If you have a lot of competing medical comorbidities that are much more likely to limit your life expectancy, you just don’t have to worry about prostate cancer for the most part, because most prostate cancer is slow growing,” he explained.
The review also explored recent advancements in screening techniques designed to enhance precision and minimise unnecessary biopsies. These innovations involve testing for additional prostate-related proteins in the blood and employing MRI scans to visualise the gland. Although promising, researchers caution that it is premature to determine whether these methods will significantly improve outcomes or reduce harm.
The Evolving Landscape of Prostate Cancer Management
David James from Prostate Cancer Research remarked that the review highlights the life-saving potential of screening while acknowledging the evolution in prostate cancer diagnosis and treatment over recent years. “MRI-led diagnostic pathways, more targeted biopsies, active surveillance, and newer biomarker tests are all changing the balance between the benefits and harms of screening,” he noted.
Conversely, Dr Ian Walker from Cancer Research UK pointed out that the findings underscore the reasons why a widespread screening programme is not currently in place in the UK. “While this review does highlight that the test could save one to two lives from prostate cancer for every 1,000 men screened, it also shows that around 30 more men could be diagnosed with the disease, many of whom would never have been harmed by their disease and could go on to have unnecessary treatment,” he cautioned.
Dr Matthew Hobbs from Prostate Cancer UK echoed this sentiment, asserting that while PSA screening could indeed save lives, the numbers are not compelling enough to support universal screening. He called for further research to address critical evidence gaps and to identify the safest and most effective ways to screen men, ensuring that the benefits outweigh the harms.
Why it Matters
This research underscores a critical dilemma in modern healthcare: the balance between the potential benefits of early detection and the risks of overtreatment. As prostate cancer remains a leading health issue for men, it is essential that individuals can make informed choices about screening. This study reinforces the need for transparent discussions between healthcare providers and patients, allowing men to weigh the pros and cons of PSA testing in light of their personal health situations. The findings may shape future policies and practices, ensuring that men at risk can navigate their options with clarity and confidence.
